Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 366

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 366
---
 optimal lifestyle. Rewell starts with an at -homeDNA and microbiome test kit, and once samples are processed, consumers can view unique insights on their genetic health risks, physical performance, rest and stress, ancestry, nutrition and immunity, and personal traits. These results can be viewed on Rewell’s secure digital platform, where consumers could also, during the pilot phase, schedule a telemedicine consultation with a healthcare professional to interpret their results, and receive a health plan with recommendations to target the prevention of certain health issues and achieve health objectives. 180 On January 9, 2024, OmnigenicsAI was incorporated in the Cayman Islands. On February 26, 2024, the Parent entered into a contribution agreement with OmnigenicsAI, pursuant to which Parent contributed to OmnigenicsAI all of the issued and outstanding shares in Heritas Argentina, making Heritas Argentina a wholly owned subsidiary of OmnigenicsAI. OmnigenicsAI issued 30,000,000 Company Shares to Parent in connection with the Heritas Argentina contribution. In 2025, after selling Rewell for two and a half years through a direct -to-consumer(“DTC”) model, we transitioned to a business -to-business-to-consumer(“B2B2C”) model. This strategic decision significantly impacted our operations, organizational structure, and go -to-marketstrategy. The transition was driven by the rising costs of logistics, customer acquisition, and digital marketing, which made the DTC model economically unsustainable for profitable scaling across Latin America. We initially invested heavily in market research, digital product development, user experience and user interface, and an e -commercechannel to validate consumer adoption. However, we concluded that scaling Rewell profitably through DTC across Latin America would require disproportionate investment with limited returns. The B2B2C model aligns with our broader strategy to scale through OmnigenicsAI’s laboratory consortium, including Heritas Diagnostics, and other local diagnostic laboratories. These partners, leveraging their market knowledge and trusted local relationships, are better positioned to distribute Rewell, manage customer relationships (including interpretation and coaching services where applicable), and oversee the commercialization of products such as the Continuous Evolution Kit. Under this model, we focus on test processing, platform operation, and results delivery, while partners lead distribution logistics and the customer relationships. During the DTC phase, we observed organic interest from wellness centers, healthcare professionals, and nutritionists seeking to resell Rewell, often choosing to manage the customer relationship